Coherus BioSciences Inc. (CHRS) and ObsEva SA (NASDAQ:OBSV) Contrasting side by side

As Biotechnology companies, Coherus BioSciences Inc. (NASDAQ:CHRS) and ObsEva SA (NASDAQ:OBSV) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00
ObsEva SA N/A 43900.56 73.65M -1.95 0.00

In table 1 we can see Coherus BioSciences Inc. and ObsEva SA’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% -741.7% -126.2%
ObsEva SA 0.00% -51.7% -46.9%

Liquidity

The Current Ratio and a Quick Ratio of Coherus BioSciences Inc. are 5.3 and 5.3. Competitively, ObsEva SA has 12.1 and 12.1 for Current and Quick Ratio. ObsEva SA’s better ability to pay short and long-term obligations than Coherus BioSciences Inc.

Analyst Recommendations

In next table is given Coherus BioSciences Inc. and ObsEva SA’s ratings and recommmendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 1 3.00
ObsEva SA 0 0 0 0.00

The consensus target price of Coherus BioSciences Inc. is $28, with potential upside of 129.13%.

Insider and Institutional Ownership

Coherus BioSciences Inc. and ObsEva SA has shares held by institutional investors as follows: 95.7% and 71%. Coherus BioSciences Inc.’s share held by insiders are 0.1%. Competitively, ObsEva SA has 15.51% of it’s share held by insiders.

Performance

In this table we show the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. -10.04% -20.27% -44.41% -37.81% 17.75% 13.07%
ObsEva SA 4.79% -8.66% 2.23% 0.27% 58.14% 50.2%

For the past year Coherus BioSciences Inc. has weaker performance than ObsEva SA.

Summary

On 7 of the 8 factors ObsEva SA beats Coherus BioSciences Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. The company intends to develop products for treating endometriosis, uterine fibroids, and preterm labor, as well as for enhancing clinical pregnancy and live birth rates in women undergoing IVF. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.